Terms: = Brain cancer AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987 AND Prognosis
47 results:
1. Molecular characterization and survival analysis of a cohort of glioblastoma, IDH-wildtype.
Dundar B; Alsawas M; Masaadeh A; Conway K; Snow AN; Sompallae RR; Bossler AD; Ma D; Lopes Abath Neto O
Pathol Res Pract; 2024 May; 257():155272. PubMed ID: 38631135
[TBL] [Abstract] [Full Text] [Related]
2. The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma.
Shirai Y; Ueno T; Kojima S; Ikeuchi H; Kitada R; Koyama T; Takahashi F; Takahashi K; Ichimura K; Yoshida A; Sugino H; Mano H; Narita Y; Takahashi M; Kohsaka S
J Neurooncol; 2024 Mar; 167(1):75-88. PubMed ID: 38363490
[TBL] [Abstract] [Full Text] [Related]
3. [Clinicopathological and molecular genetic characteristics of adult IDH wild-type diffuse gliomas].
Wang LM; Wang W; Liu L; Gao M; Yao YY; Zhang M; Xiong YL; Shao Y; Lu DH; Teng LH
Zhonghua Bing Li Xue Za Zhi; 2021 Jul; 50(7):734-739. PubMed ID: 34405606
[No Abstract] [Full Text] [Related]
4. Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells.
Smiley SB; Yun Y; Ayyagari P; Shannon HE; Pollok KE; Vannier MW; Das SK; Veronesi MC
Pharm Res; 2021 Jun; 38(6):1067-1079. PubMed ID: 34100216
[TBL] [Abstract] [Full Text] [Related]
5. Gene expression-based biomarkers designating glioblastomas resistant to multiple treatment strategies.
Menyhárt O; Fekete JT; Győrffy B
Carcinogenesis; 2021 Jun; 42(6):804-813. PubMed ID: 33754151
[TBL] [Abstract] [Full Text] [Related]
6. Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast cancer.
Yang X; Wu D; Yuan S
Technol Cancer Res Treat; 2020; 19():1533033820962140. PubMed ID: 33034269
[TBL] [Abstract] [Full Text] [Related]
7. Incorporating genomic signatures into surgical and medical decision-making for elderly glioblastoma patients.
Ene CI; Cimino PJ; Fine HA; Holland EC
Neurosurg Focus; 2020 Oct; 49(4):E11. PubMed ID: 33002863
[TBL] [Abstract] [Full Text] [Related]
8. Primary resistance to first-generation EGFR-TKIs induced by mdm2 amplification in NSCLC.
Sun D; Zhu Y; Zhu J; Tao J; Wei X; Wo Y; Hou H
Mol Med; 2020 Jul; 26(1):66. PubMed ID: 32611363
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic significance of MGMT methylation and expression of MGMT, P53, EGFR, mdm2 and PTEN in glioblastoma multiforme.
Limam S; Missaoui N; Abdessayed N; Mestiri S; Selmi B; Mokni M; Yacoubi MT
Ann Biol Clin (Paris); 2019 Jun; 77(3):307-317. PubMed ID: 31131831
[TBL] [Abstract] [Full Text] [Related]
10. Research on miR-126 in glioma targeted regulation of PTEN/PI3K/Akt and mdm2-p53 pathways.
Chen SR; Cai WP; Dai XJ; Guo AS; Chen HP; Lin GS; Lin RS
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3461-3470. PubMed ID: 31081101
[TBL] [Abstract] [Full Text] [Related]
11. Interaction with AEG-1 and mdm2 is associated with glioma development and progression and correlates with poor prognosis.
Ding Z; Zhang Z; Jin X; Chen P; Lv F; Liu D; Shen Y; Li Y; Gu X
Cell Cycle; 2019 Jan; 18(2):143-155. PubMed ID: 30560724
[TBL] [Abstract] [Full Text] [Related]
12. miR-29s function as tumor suppressors in gliomas by targeting TRAF4 and predict patient prognosis.
Shi C; Rao C; Sun C; Yu L; Zhou X; Hua D; Wang R; Luo W; Jiang Z; Zhou J; Wang Q; Yu S
Cell Death Dis; 2018 Oct; 9(11):1078. PubMed ID: 30348972
[TBL] [Abstract] [Full Text] [Related]
13. Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features.
Bielle F; Di Stefano AL; Meyronet D; Picca A; Villa C; Bernier M; Schmitt Y; Giry M; Rousseau A; Figarella-Branger D; Maurage CA; Uro-Coste E; Lasorella A; Iavarone A; Sanson M; Mokhtari K
Brain Pathol; 2018 Sep; 28(5):674-683. PubMed ID: 28976058
[TBL] [Abstract] [Full Text] [Related]
14. mdm2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance.
Ko CY; Lin CH; Chuang JY; Chang WC; Hsu TI
Mol Neurobiol; 2018 Apr; 55(4):3211-3223. PubMed ID: 28478507
[TBL] [Abstract] [Full Text] [Related]
15. Combined inhibition of AKT/mTOR and mdm2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.
Daniele S; Costa B; Zappelli E; Da Pozzo E; Sestito S; Nesi G; Campiglia P; Marinelli L; Novellino E; Rapposelli S; Martini C
Sci Rep; 2015 Apr; 5():9956. PubMed ID: 25898313
[TBL] [Abstract] [Full Text] [Related]
16. Microfoci of malignant progression in diffuse low-grade gliomas: towards the creation of an intermediate grade in glioma classification?
Pedeutour-Braccini Z; Burel-Vandenbos F; Gozé C; Roger C; Bazin A; Costes-Martineau V; Duffau H; Rigau V
Virchows Arch; 2015 Apr; 466(4):433-44. PubMed ID: 25861023
[TBL] [Abstract] [Full Text] [Related]
17. Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.
Messaoudi K; Clavreul A; Lagarce F
Drug Discov Today; 2015 Jul; 20(7):899-905. PubMed ID: 25744176
[TBL] [Abstract] [Full Text] [Related]
18. Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme.
England B; Huang T; Karsy M
Tumour Biol; 2013 Aug; 34(4):2063-74. PubMed ID: 23737287
[TBL] [Abstract] [Full Text] [Related]
19. Label-free impedimetric immunosensor for ultrasensitive detection of cancer marker Murine double minute 2 in brain tissue.
Elshafey R; Tlili C; Abulrob A; Tavares AC; Zourob M
Biosens Bioelectron; 2013 Jan; 39(1):220-5. PubMed ID: 22898660
[TBL] [Abstract] [Full Text] [Related]
20. Identification of a novel population in high-grade oligodendroglial tumors not deleted on 1p/19q using array CGH.
Talagas M; Marcorelles P; Uguen A; Redon S; Quintin-Roué I; Costa S; Férec C; Morel F; Hieu PD; De Braekeleer M
J Neurooncol; 2012 Sep; 109(2):405-13. PubMed ID: 22825724
[TBL] [Abstract] [Full Text] [Related]
[Next]
